261 related articles for article (PubMed ID: 23394379)
21. Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach.
Zargar AA
Drug Dev Res; 2024 Jun; 85(4):e22220. PubMed ID: 38845229
[TBL] [Abstract][Full Text] [Related]
22. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
[TBL] [Abstract][Full Text] [Related]
23. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
Poulakos M; Machin JD; Pauly J; Grace Y
J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
[TBL] [Abstract][Full Text] [Related]
24. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
[TBL] [Abstract][Full Text] [Related]
25. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
[TBL] [Abstract][Full Text] [Related]
27. The role of integrin antagonists in the treatment of inflammatory bowel disease.
Beniwal-Patel P; Saha S
Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K
Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab.
Wichmann A; Krugliak Cleveland N; Rubin DT
Am J Gastroenterol; 2016 Apr; 111(4):577. PubMed ID: 27125715
[No Abstract] [Full Text] [Related]
30. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
Hommes DW; Mikhajlova TL; Stoinov S; Stimac D; Vucelic B; Lonovics J; Zákuciová M; D'Haens G; Van Assche G; Ba S; Lee S; Pearce T
Gut; 2006 Aug; 55(8):1131-7. PubMed ID: 16507585
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
[TBL] [Abstract][Full Text] [Related]
32. A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study.
Cummings F; Gaya DR; Levison S; Subramanian S; Owen G; Rathmell A; Glen F; Demuth D; Meadowcroft S; Irving PM
Medicine (Baltimore); 2019 Mar; 98(9):e14681. PubMed ID: 30817598
[TBL] [Abstract][Full Text] [Related]
33. A product review of vedolizumab in inflammatory bowel disease.
Battat R; Dulai PS; Jairath V; Vande Casteele N
Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
[TBL] [Abstract][Full Text] [Related]
34. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
35. Crohn's disease: a review of treatment options and current research.
Bandzar S; Gupta S; Platt MO
Cell Immunol; 2013; 286(1-2):45-52. PubMed ID: 24321565
[TBL] [Abstract][Full Text] [Related]
36. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
[TBL] [Abstract][Full Text] [Related]
37. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
38. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
39. Introducing vedolizumab to clinical practice: who, when, and how?
Bryant RV; Sandborn WJ; Travis SP
J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
[TBL] [Abstract][Full Text] [Related]
40. Vedolizumab: first global approval.
Poole RM
Drugs; 2014 Jul; 74(11):1293-303. PubMed ID: 24985716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]